Answers are grounded in this paper and cite their sources.
Background Although delirium superimposed on dementia (DSD) is a complex clinical phenomenon with significant consequences, such as accelerated functional decline, prolonged hospitalization, high rates of institutionalization and mortality, the level of evidence for interventions targeting this condition is insufficient. This systematic review aimed to evaluate the efficacy and safety of pharmacological and non-pharmacological therapies for adult patients diagnosed with DSD. Methods PubMed/MEDLINE, Scopus, and Web of Science were searched from inception to 1 August 2026, supplemented by Google Scholar, citation searching, and reference-list screening for comparative studies evaluating interventions focused on established DSD, and a targeted search of China National Knowledge Infrastructure (CNKI). Risk of bias in the included randomized trials was assessed using RoB 2, and certainty of evidence was evaluated using GRADE. Because of clinical and methodological heterogeneity, findings were synthesized narratively. Results Five full-text randomized studies involving 510 randomized participants were included: two cognitive-stimulation studies ( N = 299), one light-therapy study ( N = 69 randomized; 61 analyzed), and two trials of quetiapine with adjunctive Annao tablets ( N = 100) or naloxone ( N = 42), each versus quetiapine alone. The larger cognitive-stimulation trial enrolled participants with full or subsyndromal delirium and found no improvement in delirium-free days or delirium severity, although executive function and post-acute length of stay favored the intervention. Light therapy was associated with lower reported Confusion Assessment Method and Neuropsychiatric Inventory scores, but a four-week caregiver-burden benefit was uncertain; methodological limitations and unclear full-delirium eligibility lower confidence in these findings. Adjunctive Annao tablets were associated with earlier symptomatic improvement and short-term cognitive and functional signals; however, the open-label design and uncertain Delirium Rating Scale scoring precluded definitive conclusions. Naloxone was associated with improvements in reported delirium scores and cognition, without a demonstrated functional advantage; unclear scale scoring, procedural limitations, and statistical inconsistencies limited interpretation. Overall, in the included studies, evidence certainty was low or very low, and safety reporting was limited. Conclusion Direct comparative evidence for treating established DSD is sparse, heterogeneous, and of reduced methodological quality. The evidence does not establish a preferred adjunctive treatment or demonstrate that all adjunctive interventions are ineffective. Existing guidance supports cause-directed and multicomponent supportive care, but rigorous DSD-specific multicentre trials remain necessary. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261336276 , identifier CRD420261336276.
No takes yet. Share an insight, caveat, or question.
Vasiliu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: